Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Day One Biopharmaceuticals, Inc. (DAWN) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Day One Biopharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1845337.
Total stock buying since 2021: $80,138,683.
Total stock sales since 2021: $73,171,147.
Total stock option exercises since 2021: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 76,084 | $610,701 | 203,014 | $0 |
| 2024 | 0 | $0 | 448,796 | $7,067,738 | 189,336 | $0 |
| 2023 | 1,475,454 | $14,978,750 | 153,490 | $2,941,452 | 77,092 | $0 |
| 2022 | 2,840,196 | $42,551,933 | 2,682,014 | $54,846,522 | 48,992 | $0 |
| 2021 | 1,413,000 | $22,608,000 | 417,482 | $7,704,734 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 28,295 | $191,470 | 71,184 | $0 |
| 2025-05 | 0 | $0 | 26,725 | $167,243 | 71,183 | $0 |
| 2025-02 | 0 | $0 | 21,064 | $251,988 | 60,647 | $0 |
| 2024-12 | 0 | $0 | 30,000 | $399,330 | 0 | $0 |
| 2024-11 | 0 | $0 | 58,027 | $881,259 | 47,334 | $0 |
| 2024-10 | 0 | $0 | 500 | $8,010 | 0 | $0 |
| 2024-09 | 0 | $0 | 30,000 | $426,690 | 0 | $0 |
| 2024-08 | 0 | $0 | 18,748 | $262,451 | 47,334 | $0 |
| 2024-07 | 0 | $0 | 20,000 | $320,220 | 0 | $0 |
| 2024-06 | 0 | $0 | 40,000 | $510,480 | 0 | $0 |
| 2024-05 | 0 | $0 | 165,740 | $2,918,972 | 47,334 | $0 |
| 2024-04 | 0 | $0 | 10,000 | $160,159 | 0 | $0 |
| 2024-03 | 0 | $0 | 40,000 | $617,380 | 0 | $0 |
| 2024-02 | 0 | $0 | 35,781 | $562,787 | 47,334 | $0 |
| 2023-11 | 0 | $0 | 10,085 | $117,891 | 28,161 | $0 |
| 2023-10 | 1,475,454 | $14,978,750 | 0 | $0 | 0 | $0 |
| 2023-08 | 0 | $0 | 5,922 | $82,076 | 19,809 | $0 |
| 2023-06 | 0 | $0 | 1,229 | $19,664 | 0 | $0 |
| 2023-05 | 0 | $0 | 4,751 | $62,341 | 14,561 | $0 |
| 2023-03 | 0 | $0 | 47,500 | $895,890 | 0 | $0 |
| 2023-02 | 0 | $0 | 49,003 | $1,015,246 | 14,561 | $0 |
| 2023-01 | 0 | $0 | 35,000 | $748,344 | 0 | $0 |
| 2022-12 | 0 | $0 | 24,358 | $531,781 | 0 | $0 |
| 2022-11 | 0 | $0 | 34,100 | $722,802 | 30,620 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-18 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 16,058 | 6.77 | 108,664 |
| 2025-08-18 | Merendino Lauren (Chief Commercial Officer) | Sale | 3,766 | 6.77 | 25,484 |
| 2025-08-18 | Dubow Adam (Gen Counsel & Secretary) | Sale | 4,365 | 6.77 | 29,537 |
| 2025-08-18 | York Charles N Ii (COO and CFO) | Sale | 4,106 | 6.77 | 27,785 |
| 2025-08-15 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Option Ex | 31,686 | .00 | 0 |
| 2025-08-15 | Merendino Lauren (Chief Commercial Officer) | Option Ex | 10,536 | .00 | 0 |
| 2025-08-15 | Dubow Adam (Gen Counsel & Secretary) | Option Ex | 12,087 | .00 | 0 |
| 2025-08-15 | York Charles N Ii (COO and CFO) | Option Ex | 16,875 | .00 | 0 |
| 2025-05-16 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 13,964 | 6.26 | 87,386 |
| 2025-05-16 | Merendino Lauren (Chief Commercial Officer) | Sale | 3,927 | 6.26 | 24,575 |
| 2025-05-16 | Dubow Adam (GENERAL COUNSEL) | Sale | 4,552 | 6.26 | 28,486 |
| 2025-05-16 | York Charles N Ii (COO, CFO AND SECRETARY) | Sale | 4,282 | 6.26 | 26,796 |
| 2025-05-15 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Option Ex | 31,686 | .00 | 0 |
| 2025-05-15 | Merendino Lauren (Chief Commercial Officer) | Option Ex | 10,536 | .00 | 0 |
| 2025-05-15 | Dubow Adam (GENERAL COUNSEL) | Option Ex | 12,086 | .00 | 0 |
| 2025-05-15 | York Charles N Ii (COO, CFO AND SECRETARY) | Option Ex | 16,875 | .00 | 0 |
| 2025-02-18 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 12,048 | 11.96 | 144,130 |
| 2025-02-18 | Dubow Adam (GENERAL COUNSEL) | Sale | 4,646 | 11.96 | 55,580 |
| 2025-02-18 | York Charles N Ii (COO, CFO AND SECRETARY) | Sale | 4,370 | 11.96 | 52,278 |
| 2025-02-15 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Option Ex | 31,686 | .00 | 0 |
| 2025-02-15 | Dubow Adam (GENERAL COUNSEL) | Option Ex | 12,086 | .00 | 0 |
| 2025-02-15 | York Charles N Ii (COO, CFO AND SECRETARY) | Option Ex | 16,875 | .00 | 0 |
| 2024-12-10 | Blackman Samuel C. (HEAD OF R&D) | Sale | 30,000 | 13.31 | 399,330 |
| 2024-11-18 | Blackman Samuel C. (HEAD OF R&D) | Sale | 2,206 | 13.21 | 29,141 |
| 2024-11-18 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 10,554 | 13.21 | 139,418 |
| 2024-11-18 | Dubow Adam (GENERAL COUNSEL) | Sale | 3,165 | 13.21 | 41,809 |
| 2024-11-18 | York Charles N Ii (COO, CFO AND SECRETARY) | Sale | 2,602 | 13.21 | 34,372 |
| 2024-11-15 | Blackman Samuel C. (HEAD OF R&D) | Option Ex | 8,686 | .00 | 0 |
| 2024-11-15 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Option Ex | 19,999 | .00 | 0 |
| 2024-11-15 | Dubow Adam (GENERAL COUNSEL) | Option Ex | 8,399 | .00 | 0 |
| 2024-11-15 | York Charles N Ii (COO, CFO AND SECRETARY) | Option Ex | 10,250 | .00 | 0 |
| 2024-11-11 | Blackman Samuel C. (HEAD OF R&D) | Sale | 10,000 | 16.10 | 160,990 |
| 2024-11-08 | Blackman Samuel C. (HEAD OF R&D) | Sale | 18,255 | 16.17 | 295,238 |
| 2024-11-07 | Blackman Samuel C. (HEAD OF R&D) | Sale | 11,245 | 16.03 | 180,291 |
| 2024-10-31 | Blackman Samuel C. (HEAD OF R&D) | Sale | 500 | 16.02 | 8,010 |
| 2024-09-10 | Blackman Samuel C. (HEAD OF R&D) | Sale | 30,000 | 14.22 | 426,690 |
| 2024-08-16 | Blackman Samuel C. (HEAD OF R&D) | Sale | 2,232 | 14.00 | 31,245 |
| 2024-08-16 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 10,681 | 14.00 | 149,523 |
| 2024-08-16 | Dubow Adam (GENERAL COUNSEL) | Sale | 3,202 | 14.00 | 44,824 |
| 2024-08-16 | York Charles N Ii (COO, CFO AND SECRETARY) | Sale | 2,633 | 14.00 | 36,859 |
| 2024-08-15 | Blackman Samuel C. (HEAD OF R&D) | Option Ex | 8,686 | .00 | 0 |
| 2024-08-15 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Option Ex | 19,999 | .00 | 0 |
| 2024-08-15 | Dubow Adam (GENERAL COUNSEL) | Option Ex | 8,399 | .00 | 0 |
| 2024-08-15 | York Charles N Ii (COO, CFO AND SECRETARY) | Option Ex | 10,250 | .00 | 0 |
| 2024-07-16 | Blackman Samuel C. (HEAD OF R&D) | Sale | 20,000 | 16.01 | 320,220 |
| 2024-06-21 | Ramasastry Saira | Sale | 10,000 | 13.19 | 131,880 |
| 2024-06-10 | Blackman Samuel C. (HEAD OF R&D) | Sale | 30,000 | 12.62 | 378,600 |
| 2024-05-16 | Blackman Samuel C. (HEAD OF R&D) | Sale | 2,267 | 16.08 | 36,451 |
| 2024-05-16 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 7,873 | 16.08 | 126,589 |
| 2024-05-16 | Dubow Adam (GENERAL COUNSEL) | Sale | 3,253 | 16.08 | 52,304 |
| 2024-05-16 | York Charles N Ii (COO, CFO AND SECRETARY) | Sale | 2,675 | 16.08 | 43,011 |
| 2024-05-15 | Blackman Samuel C. (HEAD OF R&D) | Option Ex | 8,686 | .00 | 0 |
| 2024-05-15 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Option Ex | 19,999 | .00 | 0 |
| 2024-05-15 | Dubow Adam (GENERAL COUNSEL) | Option Ex | 8,399 | .00 | 0 |
| 2024-05-15 | York Charles N Ii (COO, CFO AND SECRETARY) | Option Ex | 10,250 | .00 | 0 |
| 2024-05-10 | Blackman Samuel C. (HEAD OF R&D) | Sale | 10,000 | 16.37 | 163,740 |
| 2024-05-03 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 9,154 | 17.85 | 163,417 |
| 2024-05-03 | York Charles N Ii (COO, CFO AND SECRETARY) | Sale | 8,078 | 17.85 | 144,216 |
| 2024-05-02 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 6 | 17.94 | 107 |
| 2024-05-02 | York Charles N Ii (COO, CFO AND SECRETARY) | Sale | 200 | 17.90 | 3,579 |
| 2024-05-01 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 70,051 | 17.88 | 1,252,161 |
| 2024-05-01 | York Charles N Ii (COO, CFO AND SECRETARY) | Sale | 52,183 | 17.89 | 933,397 |
| 2024-04-18 | Blackman Samuel C. (HEAD OF R&D) | Sale | 10,000 | 16.02 | 160,159 |
| 2024-03-25 | Blackman Samuel C. (HEAD OF R&D) | Sale | 10,000 | 16.01 | 160,060 |
| 2024-03-11 | Blackman Samuel C. (HEAD OF R&D) | Sale | 30,000 | 15.24 | 457,320 |
| 2024-02-27 | Blackman Samuel C. (HEAD OF R&D) | Sale | 20,000 | 16.11 | 322,160 |
| 2024-02-16 | Blackman Samuel C. (HEAD OF RESEARCH AND DEVELOPME) | Sale | 2,258 | 15.25 | 34,429 |
| 2024-02-16 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Sale | 7,615 | 15.25 | 116,113 |
| 2024-02-16 | Dubow Adam (GENERAL COUNSEL) | Sale | 3,242 | 15.25 | 49,434 |
| 2024-02-16 | York Charles N Ii (COO, CFO AND SECRETARY) | Sale | 2,666 | 15.25 | 40,651 |
| 2024-02-15 | Blackman Samuel C. (HEAD OF RESEARCH AND DEVELOPME) | Option Ex | 8,686 | .00 | 0 |
| 2024-02-15 | Bender Jeremy (CHIEF EXECUTIVE OFFICER) | Option Ex | 19,999 | .00 | 0 |
| 2024-02-15 | Dubow Adam (GENERAL COUNSEL) | Option Ex | 8,399 | .00 | 0 |
| 2024-02-15 | York Charles N Ii (COO, CFO AND SECRETARY) | Option Ex | 10,250 | .00 | 0 |
| 2023-11-16 | Blackman Samuel C. (Head of Research and Developme) | Sale | 709 | 11.69 | 8,288 |
| 2023-11-16 | Bender Jeremy (Chief Executive Officer) | Sale | 3,107 | 11.69 | 36,320 |
| 2023-11-16 | Dubow Adam (General Counsel) | Sale | 5,313 | 11.69 | 62,108 |
| 2023-11-16 | York Charles N Ii (COO, CFO and Secretary) | Sale | 956 | 11.69 | 11,175 |
| 2023-11-15 | Blackman Samuel C. (Head of Research and Developme) | Option Ex | 2,624 | .00 | 0 |
| 2023-11-15 | Bender Jeremy (Chief Executive Officer) | Option Ex | 8,312 | .00 | 0 |
| 2023-11-15 | Dubow Adam (General Counsel) | Option Ex | 13,600 | .00 | 0 |
| 2023-11-15 | York Charles N Ii (COO, CFO and Secretary) | Option Ex | 3,625 | .00 | 0 |
| 2023-10-20 | Blavatnik Len (Other) | Buy | 111,387 | 9.97 | 1,110,862 |
| 2023-10-19 | Blavatnik Len (Other) | Buy | 384,400 | 10.06 | 3,867,448 |
| 2023-10-18 | Blavatnik Len (Other) | Buy | 979,667 | 10.21 | 10,000,440 |
| 2023-08-17 | Blackman Samuel C. (Head of Research and Developme) | Sale | 1,336 | 13.86 | 18,516 |
| 2023-08-17 | Bender Jeremy (Chief Executive Officer) | Sale | 2,996 | 13.86 | 41,524 |
| 2023-08-17 | York Charles N Ii (COO, CFO and Secretary) | Sale | 922 | 13.86 | 12,778 |
| 2023-08-15 | Blackman Samuel C. (Head of Research and Developme) | Option Ex | 5,248 | .00 | 0 |
| 2023-08-15 | Bender Jeremy (Chief Executive Officer) | Option Ex | 8,312 | .00 | 0 |
| 2023-08-15 | York Charles N Ii (COO, CFO and Secretary) | Option Ex | 3,625 | .00 | 0 |
| 2023-06-05 | Blackman Samuel C. (Chief Medical Officer) | Sale | 1,229 | 16.00 | 19,664 |
| 2023-05-16 | Blackman Samuel C. (Chief Medical Officer) | Sale | 692 | 13.12 | 9,080 |
| 2023-05-16 | Bender Jeremy (Chief Executive Officer) | Sale | 3,104 | 13.12 | 40,730 |
| 2023-05-16 | York Charles N Ii (COO, CFO and Secretary) | Sale | 955 | 13.12 | 12,531 |
| 2023-05-15 | Blackman Samuel C. (Chief Medical Officer) | Option Ex | 2,624 | .00 | 0 |
| 2023-05-15 | Bender Jeremy (Chief Executive Officer) | Option Ex | 8,312 | .00 | 0 |
| 2023-05-15 | York Charles N Ii (COO, CFO and Secretary) | Option Ex | 3,625 | .00 | 0 |
| 2023-03-10 | Blackman Samuel C. (Chief Medical Officer) | Sale | 10,000 | 18.05 | 180,479 |
| 2023-03-07 | Bender Jeremy (Chief Executive Officer) | Sale | 12,500 | 20.01 | 250,112 |
| 2023-03-01 | Grant Julie Papanek (Director) | Sale | 25,000 | 18.61 | 465,299 |
| 2023-02-17 | York Charles N Ii (COO, CFO and Secretary) | Sale | 9,377 | 20.03 | 187,793 |
| 2023-02-16 | Blackman Samuel C. (Chief Medical Officer) | Sale | 674 | 19.57 | 13,192 |
| 2023-02-16 | Bender Jeremy (Chief Executive Officer) | Sale | 3,022 | 19.57 | 59,149 |
| 2023-02-16 | York Charles N Ii (COO, CFO and Secretary) | Sale | 930 | 19.57 | 18,202 |
| 2023-02-15 | Blackman Samuel C. (Chief Medical Officer) | Option Ex | 2,624 | .00 | 0 |
| 2023-02-15 | Bender Jeremy (Chief Executive Officer) | Option Ex | 8,312 | .00 | 0 |
| 2023-02-15 | York Charles N Ii (COO, CFO and Secretary) | Option Ex | 3,625 | .00 | 0 |
| 2023-02-10 | Blackman Samuel C. (Chief Medical Officer) | Sale | 10,000 | 20.07 | 200,660 |
| 2023-02-01 | Grant Julie Papanek (Director) | Sale | 25,000 | 21.45 | 536,250 |
| 2023-01-20 | York Charles N Ii (COO, CFO and Secretary) | Sale | 10,000 | 22.75 | 227,520 |
| 2023-01-03 | Grant Julie Papanek (Director) | Sale | 25,000 | 20.83 | 520,824 |
| 2022-12-08 | Grant Julie Papanek (Director) | Sale | 4,358 | 22.08 | 96,211 |
| 2022-12-02 | Grant Julie Papanek (Director) | Sale | 5,000 | 21.55 | 107,725 |
| 2022-12-01 | Blackman Samuel C. (Chief Medical Officer) | Sale | 10,000 | 21.77 | 217,700 |
| 2022-12-01 | Grant Julie Papanek (Director) | Sale | 5,000 | 22.03 | 110,145 |
| 2022-11-21 | Bender Jeremy (Chief Executive Officer) | Sale | 12,500 | 21.06 | 263,237 |
| 2022-11-21 | York Charles N Ii (COO, CFO and Secretary) | Sale | 10,000 | 21.06 | 210,640 |
| 2022-11-16 | Blackman Samuel C. (Chief Medical Officer) | Sale | 1,131 | 21.46 | 24,270 |
| 2022-11-16 | Bender Jeremy (Chief Executive Officer) | Sale | 4,539 | 21.46 | 97,404 |
| 2022-11-16 | York Charles N Ii (COO, CFO and Secretary) | Sale | 1,290 | 21.46 | 27,681 |
| 2022-11-15 | Blackman Samuel C. (Chief Medical Officer) | Option Ex | 3,561 | .00 | 0 |
| 2022-11-15 | Bender Jeremy (Chief Executive Officer) | Option Ex | 10,686 | .00 | 0 |
| 2022-11-15 | York Charles N Ii (COO, CFO and Secretary) | Option Ex | 4,125 | .00 | 0 |
| 2022-10-04 | Grant Julie Papanek (Director) | Sale | 5,000 | 20.00 | 100,000 |
| 2022-10-03 | Grant Julie Papanek (Director) | Sale | 5,000 | 20.06 | 100,315 |
| 2022-10-03 | York Charles N Ii (COO, CFO and Secretary) | Sale | 10,000 | 20.05 | 200,470 |
| 2022-09-21 | Canaan Partners Xi Llc (10% Owner) | Sale | 613,603 | 18.91 | 11,606,300 |
| 2022-09-21 | Grant Julie Papanek (Director) | Sale | 613,603 | 18.91 | 11,606,300 |
| 2022-09-20 | Canaan Partners Xi Llc (10% Owner) | Sale | 148,670 | 19.80 | 2,943,666 |
| 2022-09-20 | Grant Julie Papanek (Director) | Sale | 148,670 | 19.80 | 2,943,666 |
| 2022-09-19 | Canaan Partners Xi Llc (10% Owner) | Sale | 76,725 | 20.57 | 1,578,233 |
| 2022-09-19 | Grant Julie Papanek (Director) | Sale | 76,725 | 20.57 | 1,578,233 |
| 2022-09-16 | Canaan Partners Xi Llc (10% Owner) | Sale | 115,307 | 21.79 | 2,511,962 |
| 2022-09-16 | Grant Julie Papanek (Director) | Sale | 115,307 | 21.79 | 2,511,962 |
| 2022-09-15 | Canaan Partners Xi Llc (10% Owner) | Sale | 51,281 | 23.26 | 1,192,796 |
| 2022-09-15 | Grant Julie Papanek (Director) | Sale | 51,281 | 23.26 | 1,192,796 |
| 2022-09-14 | Canaan Partners Xi Llc (10% Owner) | Sale | 106,111 | 23.98 | 2,545,072 |
| 2022-09-14 | Grant Julie Papanek (Director) | Sale | 106,111 | 23.98 | 2,545,072 |
| 2022-09-13 | Canaan Partners Xi Llc (10% Owner) | Sale | 87,647 | 24.70 | 2,164,880 |
| 2022-09-13 | Grant Julie Papanek (Director) | Sale | 87,647 | 24.70 | 2,164,880 |
| 2022-09-02 | Grant Papanek Julie (Director) | Sale | 5,000 | 23.82 | 119,110 |
| 2022-09-01 | Blackman Samuel C. (Chief Medical Officer) | Sale | 10,000 | 23.47 | 234,680 |
| 2022-09-01 | Bender Jeremy (Chief Executive Officer) | Sale | 25,000 | 23.47 | 586,774 |
| 2022-09-01 | Grant Papanek Julie (Director) | Sale | 5,000 | 23.50 | 117,515 |
| 2022-09-01 | York Charles N Ii (COO, CFO and Secretary) | Sale | 10,000 | 23.48 | 234,790 |
| 2022-08-16 | Blackman Samuel C. (Chief Medical Officer) | Sale | 941 | 24.31 | 22,875 |
| 2022-08-16 | Bender Jeremy (Chief Executive Officer) | Sale | 4,003 | 24.31 | 97,312 |
| 2022-08-16 | York Charles N Ii (COO, CFO and Secretary) | Sale | 1,089 | 24.31 | 26,473 |
| 2022-08-15 | Blackman Samuel C. (Chief Medical Officer) | Option Ex | 3,561 | .00 | 0 |
| 2022-08-15 | Bender Jeremy (Chief Executive Officer) | Option Ex | 10,686 | .00 | 0 |
| 2022-08-15 | York Charles N Ii (COO, CFO and Secretary) | Option Ex | 4,125 | .00 | 0 |
| 2022-08-05 | Grant Papanek Julie (Director) | Sale | 5,000 | 20.00 | 100,000 |
| 2022-08-04 | Bender Jeremy (Chief Executive Officer) | Sale | 12,500 | 20.00 | 250,025 |
| 2022-08-04 | Grant Papanek Julie (Director) | Sale | 5,000 | 20.00 | 100,005 |
| 2022-08-04 | York Charles N Ii (COO, CFO and Secretary) | Sale | 10,000 | 20.05 | 200,539 |
| 2022-08-01 | Blackman Samuel C. (Chief Medical Officer) | Sale | 10,000 | 16.88 | 168,810 |
| 2022-07-18 | Bender Jeremy (Chief Executive Officer) | Sale | 2,600 | 20.00 | 52,002 |
| 2022-07-18 | Grant Papanek Julie (Director) | Sale | 2,600 | 20.00 | 52,000 |
| 2022-07-18 | York Charles N Ii (COO, CFO and Secretary) | Sale | 2,500 | 20.00 | 50,000 |
| 2022-07-08 | Bender Jeremy (Chief Executive Officer) | Sale | 1,795 | 20.00 | 35,900 |
| 2022-07-08 | Grant Papanek Julie (Director) | Sale | 1,242 | 20.00 | 24,840 |
| 2022-07-08 | York Charles N Ii (COO, CFO and Secretary) | Sale | 1,416 | 20.00 | 28,320 |
| 2022-07-05 | Bender Jeremy (Chief Executive Officer) | Sale | 857 | 20.00 | 17,140 |
| 2022-07-05 | Grant Papanek Julie (Director) | Sale | 800 | 20.00 | 16,000 |
| 2022-07-05 | York Charles N Ii (COO, CFO and Secretary) | Sale | 800 | 20.00 | 16,000 |
| 2022-07-01 | Blackman Samuel C. (Chief Medical Officer) | Sale | 10,000 | 19.14 | 191,400 |
| 2022-07-01 | Bender Jeremy (Chief Executive Officer) | Sale | 1,746 | 20.00 | 34,920 |
| 2022-07-01 | Grant Papanek Julie (Director) | Sale | 1,000 | 20.00 | 20,000 |
| 2022-07-01 | York Charles N Ii (COO, CFO and Secretary) | Sale | 1,479 | 20.00 | 29,580 |
| 2022-06-17 | Gladstone Michael (Director) | Buy | 766,667 | 15.00 | 11,500,005 |
| 2022-06-17 | Atlas Venture Associates Opportunity I, Llc (10% Owner) | Buy | 766,667 | 15.00 | 11,500,005 |
| 2022-06-17 | Blavatnik Len (Other) | Buy | 1,200,000 | 15.00 | 18,000,000 |
| 2022-06-15 | Blackman Samuel C. (Chief Medical Officer) | Sale | 50,000 | 16.26 | 813,150 |
| 2022-01-20 | Blavatnik Len (Other) | Buy | 4,615 | 14.73 | 67,974 |
| 2022-01-19 | Blavatnik Len (Other) | Buy | 58,818 | 14.70 | 864,565 |
| 2022-01-18 | Blavatnik Len (Other) | Buy | 43,429 | 14.26 | 619,384 |
| 2022-01-03 | Blackman Samuel C. (Chief Medical Officer) | Sale | 10,000 | 17.18 | 171,789 |
| 2021-12-08 | Takeda Ventures, Inc. | Sale | 110,338 | 18.03 | 1,989,394 |
| 2021-12-07 | Takeda Ventures, Inc. | Sale | 186,935 | 18.96 | 3,545,222 |
| 2021-12-06 | Takeda Ventures, Inc. | Sale | 97,692 | 18.05 | 1,763,340 |
| 2021-12-03 | Takeda Ventures, Inc. | Sale | 12,517 | 18.47 | 231,188 |
| 2021-12-01 | Blackman Samuel C. (Chief Medical Officer) | Sale | 10,000 | 17.56 | 175,590 |
| 2021-06-01 | Canaan Partners Xi Llc (10% Owner) | Buy | 13,000 | 16.00 | 208,000 |
| 2021-06-01 | Atlas Venture Associates Xi, Llc (10% Owner) | Buy | 500,000 | 16.00 | 8,000,000 |
| 2021-06-01 | Josey John A. (Director) | Buy | 7,000 | 16.00 | 112,000 |
| 2021-06-01 | Becker Daniel J. (Director) | Buy | 5,000 | 16.00 | 80,000 |
| 2021-06-01 | Grant Papanek Julie (Director) | Buy | 13,000 | 16.00 | 208,000 |
| 2021-06-01 | Blavatnik Len (Other) | Buy | 875,000 | 16.00 | 14,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of DAWN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Day One Biopharmaceuticals, Inc. (symbol DAWN, CIK number 1845337) see the Securities and Exchange Commission (SEC) website.